Treatment of sepsis-associated acute respiratory distress syndrome by integrated traditional Chinese and Western medicine
-
摘要: 脓毒症相关急性呼吸窘迫综合征作为临床常见急危重症，发病率及死亡率高，康复率低。西医治疗主要是加强脓毒症集束化治疗，包括抗感染、液体复苏、免疫调节、呼吸支持等手段。然而，由于脓毒症的复杂性与紧迫性，现在治疗仍存在诸多未知与局限。本文在总结西医治疗现状的基础上，介绍了中医的病机认识，中药单体、中药复方、中药制剂、针刺、外治等方法在抑制炎症反应、改善呼吸功能、降低死亡率上的巨大作用，以及“截断扭转”与“全程补虚”思想在祛除病原、防止传变上的运用与实践，以期为脓毒症相关急性呼吸窘迫综合征的中西医结合治疗提供新思路和方法。Abstract: Sepsis-assocaited acute respiratory distress syndrome is a common acute and critical illness with high morbidity, high mortality and low recovery rate. Western medicine treatment is mainly to strengthen the bundle treatment, including anti-infection, fluid resuscitation, immune regulation, respiratory support and other means. However, due to the complexity and urgency of sepsis, there are still many unknowns and limitations in treatment. On the basis of summarizing the current situation of Western medicine treatment, this paper introduces the pathogenesis of traditional Chinese medicine, the great effects of TCM monomer(TCM), TCM compound, TCM preparation, acupuncture, external treatment and other methods in inhibiting inflammation, improving respiratory function and reducing mortality, and the application and practice of the ideas of "truncation and reversal" and "full tonification of deficiency" in removing pathogens and preventing transmission. In order to provide a new idea and method for the combination of Chinese and Western medicine in the treatment of sepsis-associated acute respiratory distress syndrome.
-
-
[1] Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021[J]. Intensive Care Med, 2021, 47(11): 1181-1247. doi: 10.1007/s00134-021-06506-y
[2] Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the global burden of disease study[J]. Lancet, 2020, 395(10219): 200-211. doi: 10.1016/S0140-6736(19)32989-7
[3] Dong R, Liu W, Weng L, et al. Temporal trends of sepsis-related mortality in China, 2006-2020: a population-based study[J]. Ann Intensive Care, 2023, 13(1): 71. doi: 10.1186/s13613-023-01166-1
[4] Sun B, Lei M, Zhang J, et al. Acute lung injury caused by sepsis: how does it happen?[J]. Front Med(Lausanne), 2023, 10: 1289194.
[5] Bos LDJ, Ware LB. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes[J]. Lancet, 2022, 400(10358): 1145-1156. doi: 10.1016/S0140-6736(22)01485-4
[6] Matthay MA, Arabi Y, Arroliga AC, et al. A new global definition of acute respiratory distress syndrome[J]. Am J Respir Crit Care Med, 2024, 209(1): 37-47. doi: 10.1164/rccm.202303-0558WS
[7] Grasselli G, Calfee CS, Camporota L, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies[J]. Intensive Care Med, 2023, 49(7): 727-759. doi: 10.1007/s00134-023-07050-7
[8] Marik PE, Linde-Zwirble WT, Bittner EA, et al. Fluid administration in severe sepsis and septic shock, patterns and outcomes: an analysis of a large national database[J]. Intensive Care Med, 2017, 43(5): 625-632. doi: 10.1007/s00134-016-4675-y
[9] Corl KA, Levy MM, Holder AL, et al. Moderate IV fluid resuscitation is associated with decreased sepsis mortality[J]. Crit Care Med, 2024, 52(11): e557-e567. doi: 10.1097/CCM.0000000000006394
[10] Prkno A, Wacker C, Brunkhorst FM, et al. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock: a systematic review and meta-analysis[J]. Crit Care, 2013, 17(6): R291. doi: 10.1186/cc13157
[11] Chaudhuri D, Nei AM, Rochwerg B, et al. 2024 focused update: guidelines on use of corticosteroids in sepsis, acute respiratory distress syndrome, and community-acquired pneumonia[J]. Crit Care Med, 2024, 52(5): e219-e233. doi: 10.1097/CCM.0000000000006172
[12] Chen W, Janz DR, Bastarache JA, et al. Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: a propensity-adjusted analysis[J]. Crit Care Med, 2015, 43(4): 801-807. doi: 10.1097/CCM.0000000000000789
[13] Lu ZQ, Fang P, Xia DL, et al. The impact of aspirin exposure prior to intensive care unit admission on the outcomes for patients with sepsis-associated acute respiratory failure[J]. Front Pharmacol, 2023, 14: 1125611. doi: 10.3389/fphar.2023.1125611
[14] Zhao H, Wang H, Sun F, et al. High-flow nasal Cannula oxygen therapy is superior to conventional oxygen therapy but not to noninvasive mechanical ventilation on intubation rate: a systematic review and meta-analysis[J]. Crit Care, 2017, 21(1): 184. doi: 10.1186/s13054-017-1760-8
[15] Grieco DL, Maggiore SM, Roca O, et al. Non-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS[J]. Intensive Care Med, 2021, 47(8): 851-866. doi: 10.1007/s00134-021-06459-2
[16] Yau CE, Lee DYX, Vasudevan A, et al. Performance of the ROX index in predicting high flow nasal Cannula failure in COVID-19 patients: a systematic review and meta-analysis[J]. Crit Care, 2023, 27(1): 320. doi: 10.1186/s13054-023-04567-7
[17] Brower RG, Lanken PN, MacIntyre N, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome[J]. N Engl J Med, 2004, 351(4): 327-336. doi: 10.1056/NEJMoa032193
[18] 曹书华, 王今达, 李银平. 从"菌毒并治"到"四证四法": 关于中西医结合治疗多器官功能障碍综合征辨证思路的深入与完善[J]. 中国危重病急救医学, 2005, 17(11): 641-643.
[19] He J, Si X, Ji M, et al. Effect of rhubarb on extravascular lung water in patients with acute respiratory distress syndrome[J]. Rev Assoc Med Bras(1992), 2017, 63(5): 435-440. doi: 10.1590/1806-9282.63.05.435
[20] Lai F, Zhang Y, Xie DP, et al. A systematic review of rhubarb(a traditional Chinese medicine)used for the treatment of experimental sepsis[J]. Evid Based Complement Alternat Med, 2015, 2015: 131283.
[21] Tang TY, Wang F, Liu J, et al. Rhubarb alleviates acute lung injury by modulating gut microbiota dysbiosis in mice[J]. Curr Microbiol, 2022, 79(4): 116. doi: 10.1007/s00284-022-02811-x
[22] Badshah SL, Faisal S, Muhammad A, et al. Antiviral activities of flavonoids[J]. Biomed Pharmacother, 2021, 140: 111596. doi: 10.1016/j.biopha.2021.111596
[23] Long Y, Xiang Y, Liu SY, et al. Baicalin liposome alleviates lipopolysaccharide-induced acute lung injury in mice via inhibiting TLR4/JNK/ERK/NF-κB pathway[J]. Mediators Inflamm, 2020, 2020: 8414062.
[24] Li XM, Zhang XY, Kang Y, et al. Scutellarein suppresses the production of ROS and inflammatory mediators of LPS-activated bronchial epithelial cells and attenuates acute lung injury in mice[J]. Antioxidants, 2024, 13(6): 710. doi: 10.3390/antiox13060710
[25] Zhong KQ, Huang YG, Chen R, et al. The protective effect of ginsenoside Rg1 against sepsis-induced lung injury through PI3K-Akt pathway: insights from molecular dynamics simulation and experimental validation[J]. Sci Rep, 2024, 14(1): 16071. doi: 10.1038/s41598-024-66908-y
[26] Zhang H, Sun Y, Fan ML, et al. Prevention effect of total ginsenosides and ginseng extract from Panax ginseng on cyclophosphamide-induced immunosuppression in mice[J]. Phytother Res, 2023, 37(8): 3583-3601. doi: 10.1002/ptr.7836
[27] Liu YL, Liu YJ, Liu Y, et al. Hydroxysafflor yellow A ameliorates lipopolysaccharide-induced acute lung injury in mice via modulating toll-like receptor 4 signaling pathways[J]. Int Immunopharmacol, 2014, 23(2): 649-657. doi: 10.1016/j.intimp.2014.10.018
[28] Guo XJ, Zheng M, Pan RY, et al. Hydroxysafflor yellow A(HSYA)targets the platelet-activating factor(PAF)receptor and inhibits human bronchial smooth muscle activation induced by PAF[J]. Food Funct, 2019, 10(8): 4661-4673. doi: 10.1039/C9FO00896A
[29] Jin M, Wu Y, Wang L, et al. Hydroxysafflor yellow A attenuates bleomycin-induced pulmonary fibrosis in mice[J]. Phytother Res, 2016, 30(4): 577-587. doi: 10.1002/ptr.5560
[30] 郭树明, 脱承德, 孟祥云. 宣白承气汤联合复合乳酸菌治疗脓毒症相关性ARDS的疗效分析[J]. 时珍国医国药, 2021, 32(1): 135-137. doi: 10.3969/j.issn.1008-0805.2021.01.39
[31] 王利粉, 阮俊, 林惠卿. 宣白承气汤加味结合机械通气治疗急性呼吸窘迫综合征疗效观察[J]. 辽宁中医杂志, 2024, 51(6): 103-106.
[32] Zhu HH, Wang S, Shan C, et al. Mechanism of protective effect of Xuan-Bai-Cheng-qi decoction on LPS-induced acute lung injury based on an integrated network pharmacology and RNA-sequencing approach[J]. Respir Res, 2021, 22(1): 188. doi: 10.1186/s12931-021-01781-1
[33] Wang S, Lin FF, Zhang CX, et al. Xuanbai Chengqi Decoction alleviates acute lung injury by inhibiting NLRP3 inflammasome[J]. J Ethnopharmacol, 2024, 319(Pt 2): 117227.
[34] 徐爱平, 贺贤丽, 游莎. 清瘟败毒饮治疗脓毒症相关性急性呼吸窘迫综合征临床观察[J]. 河北中医, 2024, 46(6): 932-935. doi: 10.3969/j.issn.1002-2619.2024.06.011
[35] 贺燕玲, 毛祥正, 李莎, 等. 基于网络药理学探讨清瘟败毒饮治疗脓毒症急性肺损伤的机制研究[J]. 中药药理与临床, 2022, 38(6): 13-20.
[36] 杨菊, 张照, 王加伟, 等. 清瘟败毒饮对脂多糖诱导急性肺损伤的改善作用及机制[J]. 中国实验方剂学杂志, 2023, 29(15): 1-13.
[37] 赵秋娟, 雷根平, 冯喆, 等. 基于核因子E2相关因子2/血红素加氧酶-1信号通路探讨益气康肺方对脂多糖感染急性肺损伤地鼠氧化损伤的影响[J]. 环球中医药, 2024, 17(9): 1724-1730.
[38] 陈剑坤, 卢月, 李际强, 等. 扶正解毒方含药血清对小鼠肺泡巨噬细胞和Ⅱ型肺泡上皮细胞共培养的炎症调控作用研究[J]. 时珍国医国药, 2023, 34(3): 554-558. doi: 10.3969/j.issn.1008-0805.2023.03.11
[39] Li CY, Wang P, Li M, et al. The current evidence for the treatment of sepsis with xuebijing injection: bioactive constituents, findings of clinical studies and potential mechanisms[J]. J Ethnopharmacol, 2021, 265: 113301. doi: 10.1016/j.jep.2020.113301
[40] Zhang M, Zheng R, Liu WJ, et al. Xuebijing injection, a Chinese patent medicine, against severe pneumonia: current research progress and future perspectives[J]. J Integr Med, 2023, 21(5): 413-422. doi: 10.1016/j.joim.2023.08.004
[41] Liu SQ, Yao C, Xie JF, et al. Effect of an herbal-based injection on 28-day mortality in patients with sepsis: the EXIT-SEP randomized clinical trial[J]. JAMA Intern Med, 2023, 183(7): 647-655. doi: 10.1001/jamainternmed.2023.0780
[42] Wang W, He Q, Wang MQ, et al. Effects of tanreqing injection on ICU mortality among ICU patients receiving mechanical ventilation: time-dependent cox regression analysis of A large registry[J]. Chin J Integr Med, 2023, 29(9): 782-790. doi: 10.1007/s11655-023-3634-z
[43] Hu CL, Li JL, Tan YS, et al. Tanreqing injection attenuates macrophage activation and the inflammatory response via the lncRNA-SNHG1/HMGB1 axis in lipopolysaccharide-induced acute lung injury[J]. Front Immunol, 2022, 13: 820718. doi: 10.3389/fimmu.2022.820718
[44] Yang WF, Liu JL, Blažeković B, et al. In vitro antibacterial effects of Tanreqing injection combined with vancomycin or linezolid against methicillin-resistant Staphylococcus aureus[J]. BMC Complement Altern Med, 2018, 18(1): 169. doi: 10.1186/s12906-018-2231-8
[45] Gu X, Gao R, Li Y, et al. Combination effect of azithromycin with TCM preparation Xiyanping injection against Klebsiella pneumoniae infection in rats[J]. Phytomedicine, 2022, 104: 154332. doi: 10.1016/j.phymed.2022.154332
[46] Chen J, Ding W, Zhang Z, et al. Shenfu injection targets the PI3K-AKT pathway to regulate autophagy and apoptosis in acute respiratory distress syndrome caused by sepsis[J]. Phytomedicine, 2024, 129: 155627. doi: 10.1016/j.phymed.2024.155627
[47] 李莉, 穆蕊, 余剑波, 等. 电针足三里穴和尺泽穴对脓毒症患者急性肺损伤的影响[J]. 中华麻醉学杂志, 2013, 33(5): 626-629. doi: 10.3760/cma.j.issn.0254-1416.2013.05.029
[48] 张玉洁, 徐淑文, 刘文美, 等. 电针预处理对脓毒症急性肺损伤大鼠肺组织中NEK7-NLRP3炎症小体激活的影响[J]. 南京中医药大学学报, 2023, 39(5): 467-473.
[49] 刘心月, 苏景超, 张新芳, 等. 电针预处理对脂多糖诱导的脓毒症急性肺损伤大鼠肺组织中血管紧张素转化酶2、血管紧张素(1-7)的影响[J]. 针刺研究, 2022, 47(8): 684-689.
[50] 逯珍花, 梁波涛, 吴佳, 等. 肺外源性急性呼吸窘迫综合征伴腹腔高压患者益气解毒通腑汤保留灌肠对血气、呼吸、腹压及胃肠功能的影响[J]. 中华中医药学刊, 2023, 41(5): 48-51.
[51] Chen MG, Wang FF, Huang LX, et al. Effect of sitting Baduanjin exercise on early rehabilitation of sepsis patients with non-invasive ventilation: a randomized controlled trial[J]. BMC Complement Med Ther, 2024, 24(1): 330.
[52] Wu XX, He CM, Liu CY, et al. Mechanisms of JinHong Formula on treating sepsis explored by randomized controlled trial combined with network pharmacology[J]. J Ethnopharmacol, 2023, 305: 116040.
[53] 张文, 方邦江, 卜建宏, 等. 锦红汤在感染性疾病中的应用及效应机制研究[J]. 中国中医基础医学杂志, 2021, 27(2): 298-301.
[54] Xu XR, Zhang W, Wu XX, et al. Effectiveness and safety of Baidu Jieduan Granules for COVID-19: a retrospective observational multicenter study[J]. Chin J Integr Med, 2022, 28(10): 885-893.
[55] Feng J, Fang BJ, Zhou DX, et al. Clinical effect of traditional Chinese medicine Shenhuang Granule in critically ill patients with COVID-19: a single-centered, retrospective, observational study[J]. J Microbiol Biotechnol, 2021, 31(3): 380-386.
[56] Zhou S, Feng J, Xie Q, et al. Traditional Chinese medicine Shenhuang Granule in patients with severe/critical COVID-19: a randomized controlled multicenter trial[J]. Phytomedicine, 2021, 89: 153612.
[57] Xu XR, Zhang W, Wu XX, et al. Analysis of mechanisms of Shenhuang Granule in treating severe COVID-19 based on network pharmacology and molecular docking[J]. J Integr Med, 2022, 20(6): 561-574.
-
计量
- 文章访问数: 87
- 施引文献: 0
下载: